Aduro BioTech, Inc. has entered an agreement granting Janssen Biotech an exclusive, worldwide license to certain product candidates for the treatment of prostate cancer based on its LADD immunotherapy platform.
Aduro is eligible to receive as much as $365 million in upfront license fees and milestone payments based on development, regulatory and commercialization milestones, should multiple programs advance to commercialization, as well as royalties on sales.
Janssen will be responsible for all research, development, manufacturing, regulatory and commercialization for the licensed products. Under a separate agreement, Aduro has granted Janssen exclusive rights to its GVAX technology for prostate cancer.
“We are pleased to provide Janssen with novel immunotherapies engineered specifically for this indication,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We believe this is an important validation of our platform strategy and we are excited to have the Janssen development team taking the lead in advancing the prostate cancer program. Separately, we look forward to continued progress with our LADD platform in a broad array of other oncology indications, including pancreatic cancer, mesothelioma, non-small cell lung cancer and glioblastoma among others.”